Market Research Logo

Birch Pollen Allergy - Pipeline Review, H1 2015

Birch Pollen Allergy - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Birch Pollen Allergy - Pipeline Review, H1 2015’, provides an overview of the Birch Pollen Allergy’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Birch Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Birch Pollen Allergy and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Birch Pollen Allergy
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Birch Pollen Allergy and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Birch Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Birch Pollen Allergy pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Birch Pollen Allergy
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Birch Pollen Allergy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Birch Pollen Allergy Overview
Therapeutics Development
Pipeline Products for Birch Pollen Allergy - Overview
Pipeline Products for Birch Pollen Allergy - Comparative Analysis
Birch Pollen Allergy - Therapeutics under Development by Companies
Birch Pollen Allergy - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Birch Pollen Allergy - Products under Development by Companies
Birch Pollen Allergy - Companies Involved in Therapeutics Development
ALK-Abello A/S
Allergopharma Joachim Ganzer KG
Anergis SA
Biomay AG
Circassia Pharmaceuticals plc
HAL Allergy BV
Stallergenes S.A.
Birch Pollen Allergy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ALK Birch Pollen Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AllerT - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Birch-SPIRE - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BM-31 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug for Birch Pollen Allergy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PL-102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rBet v1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rBet v1-FV - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Birch Pollen Allergy - Recent Pipeline Updates
Birch Pollen Allergy - Dormant Projects
Birch Pollen Allergy - Discontinued Products
Birch Pollen Allergy - Product Development Milestones
Featured News & Press Releases
Dec 11, 2014: Anergis Starts Phase II Dose Ranging Trial with Birch Pollen Allergy Vaccine AllerT
Sep 16, 2014: Anergis Reports Positive Long-Term Clinical Efficacy of Lead Compound AllerT
Apr 23, 2014: Anergis Completes Enrolment in the Long-Term Efficacy Trial of Lead Compound AllerT
Feb 27, 2014: Phase IIb Results of Anergis´ Lead Compound AllerT to be Presented at 2014 AAAAI Annual Meeting in San Diego
Oct 21, 2013: Immunology Data Further Underline the Positive Outcome of a Phase IIb Trial of Anergis's Birch Pollen Allergy Vaccine AllerT
Sep 10, 2013: Anergis Reports Positive Phase IIb Data for Birch Pollen Allergy Vaccine AllerT
Jan 23, 2013: Anergis Obtains US Patent For Lead Product AllerT
Nov 08, 2012: Long-Term Immunomodulation Induced By Anergis's COP Allergy Vaccine AllerT Extends To Fourth Year After Treatment
Nov 06, 2012: Anergis Starts European Phase IIb Clinical Trial With AllerT In Patients With Allergy To Birch Pollen
Jan 24, 2011: Anergis Obtains Core Technology Patent Protection in the US
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Birch Pollen Allergy, H1 2015
Number of Products under Development for Birch Pollen Allergy - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Birch Pollen Allergy - Pipeline by ALK-Abello A/S, H1 2015
Birch Pollen Allergy - Pipeline by Allergopharma Joachim Ganzer KG, H1 2015
Birch Pollen Allergy - Pipeline by Anergis SA, H1 2015
Birch Pollen Allergy - Pipeline by Biomay AG, H1 2015
Birch Pollen Allergy - Pipeline by Circassia Pharmaceuticals plc, H1 2015
Birch Pollen Allergy - Pipeline by HAL Allergy BV, H1 2015
Birch Pollen Allergy - Pipeline by Stallergenes S.A., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Birch Pollen Allergy Therapeutics - Recent Pipeline Updates, H1 2015
Birch Pollen Allergy - Dormant Projects, H1 2015
Birch Pollen Allergy - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Birch Pollen Allergy, H1 2015
Number of Products under Development for Birch Pollen Allergy - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report